^
Association details:
| Biomarker: | POLE mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
Excerpt:
Germline mutations or somatic mutations in POLE or POLD (synonymous mutation is excluded).
Trial ID:
Source:
Title:
A phase II clinical trial of toripalimab in advanced solid tumors with POLE/POLD1 mutation.
Published date:
01/17/2023
Excerpt:
We initiated a phase II clinical trial for non-microsatellite instability-high (non-MSI-H) patients with POLE/POLD1 mutant advanced solid tumors to investigate the treatment efficacy of toripalimab...The overall response rate was 21.4%, and the disease control rate was 57.1%. The median overall survival and median progression-free survival were 2.5 months and 28.2 months, respectively. The overall response rate of the patients with POL-EDMs and POL-non-EDMs were 66.7% and 7.1%, while the disease control rates were 66.7% and 54.5%, respectively.
DOI:
10.1200/JCO.2023.41.3_suppl.802
Trial ID:
